A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Actual Enrollment: 783 participantsAllocation: RandomizedActual Study Start Date: 21/09/2018Actual Primary Completion Date: 19/11/2021Estimated Study Completion Date: 26/02/2024Sponsor: Bristol-Myers SquibbClinical Trial Link: https://classic.clinicaltrials.gov/ct2/show/study/NCT03635983
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread